Antibody-Based Migraine Treatment
Safe and effective drug based preventative migraine treatment continues to be an elusive goal for many drug manufacturers and research scientists. Whereas the Omega migraine procedure doesn’t increase the likelihood for adverse drug side effects or dependency concerns, it can only be provided to chronic headache or migraine patients who qualify for the treatment.
The outcomes for these people have been excellent; allowing them to continue enjoying their lives free from debilitating and chronic migraine pain.
Britain’s news source, Daily Mail, recently featured an article about medical experts who are working on a new preventative migraine drug therapy based on how antibodies work in the body. American and British researchers collaborated on the clinical trials for this new migraine treatment.
The drugs work by blocking the chemical calcitonin gene-related peptide (CGRP) that gets released from nerve endings, from attaching to its neuro-receptors in the brain. Migraine physiology is believed to involve the release and binding of this chemical, which sets off a chain of events leading to pain and other symptoms. A migraine procedure works to block this pain reaction by sending electronic impulses that essentially interfere with pain messages.
Similar to how antibodies fight offending invaders within the body, these drugs attack the chemicals (CGRP) involved with jumpstarting migraine headaches. Migraine suffers have been reported to have greater levels of this substance, which causes changes within the brain. These alterations are believed to interfere with blood flow causing vasodilation, which leads to migraines.
While this news is very interesting and certainly exciting for millions of migraine sufferers, it must be tempered with the understanding that the government approval process for new drugs requires extensive research and trials, often lasting for many years. For many, preventative medication may counteract with ongoing treatment for other medical conditions, and pain medication might present other risks and concerns.
These people could benefit from a migraine procedure, if they qualify. Until these new preventative CGRP-blocking migraine drugs have been definitively proven to be effective and safe for patient use, and receive official approval, it is important to focus on getting effective and available migraine treatment.